John J. Gaudino

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

A general synthesis of 5-arylnicotinates

Wayne J. Thompson, John J. Gaudino · The Journal of Organic Chemistry · 1984 · 211 citations

Engineering, Media Standards, Databases +18

Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F. Blake, Michael Burkard, Jocelyn Chan et al. · Journal of Medicinal Chemistry · 2016 · 156 citations · Full text

Erk Kinase Activity, Cellular Pharmacology, Tumor Biology +20

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 104 citations · Full text

New approaches to enzyme regulators. Synthesis and enzymological activity of carbocyclic analogs of D-fructofuranose and D-fructofuranose-6-phosphate

Craig S. Wilcox, John J. Gaudino · Journal of the American Chemical Society · 1986 · 92 citations

Engineering, New Approaches, Altmetric Attention Score +16